During a recent government meeting, discussions centered on the treatment capabilities of a new device designed to assist individuals struggling with substance addiction. The device, while FDA-cleared specifically for opioid addiction, has shown potential for treating a range of substance use disorders, including alcohol, methamphetamines, and cocaine. However, officials clarified that it cannot be used for alcohol withdrawal due to the severe risks associated with sudden cessation.

The conversation highlighted the device's operational parameters, noting that it can be utilized for up to seven days, depending on the substance and the individual's history of use. For instance, those using fentanyl may require treatment for three to five days, while stronger substances like methadone may necessitate the full week.

Participants also raised questions about the device's effectiveness in addressing psychological issues such as depression and anxiety. While the device does not directly treat these conditions, it was noted that alleviating withdrawal symptoms can lead to improvements in overall mental health as individuals begin to regain control over their lives.

The meeting concluded with a motion to ensure that contractors involved in the treatment program are fully informed about these capabilities, emphasizing the importance of comprehensive care in addressing the multifaceted nature of addiction.